3.20
price down icon0.02%   -0.04
 
loading
Ac Immune Sa stock is traded at $3.20, with a volume of 16,918. It is down -0.02% in the last 24 hours and up +5.52% over the past month. AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
See More
Previous Close:
$3.24
Open:
$3.23
24h Volume:
16,918
Relative Volume:
0.16
Market Cap:
$324.53M
Revenue:
-
Net Income/Loss:
$-60.14M
P/E Ratio:
-3.7471
EPS:
-0.854
Net Cash Flow:
$-68.17M
1W Performance:
-8.75%
1M Performance:
+5.52%
6M Performance:
-3.01%
1Y Performance:
+6.91%
1-Day Range:
Value
$3.16
$3.3525
1-Week Range:
Value
$3.11
$3.55
52-Week Range:
Value
$2.25
$5.14

Ac Immune Sa Stock (ACIU) Company Profile

Name
Name
Ac Immune Sa
Name
Phone
-
Name
Address
-
Name
Employee
161
Name
Twitter
@AC_Immune_SA
Name
Next Earnings Date
2024-11-18
Name
Latest SEC Filings
Name
ACIU's Discussions on Twitter

Compare ACIU with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
ACIU 3.19 324.53M 0 -60.14M -68.17M -0.854
VRTX 447.21 115.74B 10.63B -479.80M -1.35B 13.33
REGN 737.75 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 586.52 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 248.92 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 102.55 24.49B 3.30B -501.07M 1.03B 11.54

Ac Immune Sa Stock (ACIU) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-01-19 Downgrade UBS Buy → Neutral
Jan-04-19 Initiated UBS Buy
Apr-05-18 Initiated H.C. Wainwright Buy
Mar-23-18 Downgrade Credit Suisse Outperform → Neutral
Oct-18-16 Initiated Credit Suisse Outperform
Oct-18-16 Initiated Jefferies Buy
Oct-18-16 Initiated Leerink Partners Outperform
View All

Ac Immune Sa Stock (ACIU) Latest News

pulisher
Nov 17, 2024

HC Wainwright Reaffirms “Buy” Rating for AC Immune (NASDAQ:ACIU) - Defense World

Nov 17, 2024
pulisher
Nov 15, 2024

AC Immune’s stock jumps after Parkinson’s therapy shows signs of benefit - Clinical Trials Arena

Nov 15, 2024
pulisher
Nov 15, 2024

AC Immune (NASDAQ:ACIU) Given "Buy" Rating at HC Wainwright - MarketBeat

Nov 15, 2024
pulisher
Nov 15, 2024

AC Immune reports interim results from Phase 2 trial of ACI-7104.056 - Yahoo Finance

Nov 15, 2024
pulisher
Nov 15, 2024

AC Immune (ACIU) Sees Stock Boost Following Positive Trial Data - Stocks Telegraph

Nov 15, 2024
pulisher
Nov 15, 2024

Short Interest in AC Immune SA (NASDAQ:ACIU) Increases By 23.5% - MarketBeat

Nov 15, 2024
pulisher
Nov 15, 2024

AC Immune SA (NASDAQ:ACIU) Short Interest Up 23.5% in October - Defense World

Nov 15, 2024
pulisher
Nov 14, 2024

AC Immune stock jumps 20% on data for Parkinson's disease drug (NASDAQ:ACIU) - Seeking Alpha

Nov 14, 2024
pulisher
Nov 14, 2024

S&P 500 Moves Lower; US Crude Oil Inventories Increase - Benzinga

Nov 14, 2024
pulisher
Nov 14, 2024

AC Immune's Active Immunotherapy Shows Antibody Responses In Early Parkinson's Patients - Benzinga

Nov 14, 2024
pulisher
Nov 14, 2024

AC Immune Phase II ACI-7104.056 success in Parkinson’s - The Pharma Letter

Nov 14, 2024
pulisher
Nov 14, 2024

AC Immune's Parkinson's vaccine shows promise in early trial - Investing.com India

Nov 14, 2024
pulisher
Nov 14, 2024

AC immune announces positive trial results for early Parkinson’s treatment - PharmaTimes

Nov 14, 2024
pulisher
Nov 14, 2024

AC Immune’s Promising Trial Results for Parkinson’s Therapy - TipRanks

Nov 14, 2024
pulisher
Nov 14, 2024

Immunotherapy in Early Parkinson’s Disease Posts Positive Interim Results from Phase 2 Study - Precision Vaccinations

Nov 14, 2024
pulisher
Nov 14, 2024

AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease - The Manila Times

Nov 14, 2024
pulisher
Nov 14, 2024

AC Immune's Parkinson's vaccine shows promise in early trial By Investing.com - Investing.com UK

Nov 14, 2024
pulisher
Nov 14, 2024

AC Immune's Parkinson's Drug Shows 16x Higher Antibody Levels in Phase 2 Trial | ACIU Stock News - StockTitan

Nov 14, 2024
pulisher
Nov 13, 2024

AC Immune to Present at the Jefferies 2024 London Healthcare Conference - Yahoo Finance

Nov 13, 2024
pulisher
Nov 12, 2024

Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights - The Manila Times

Nov 12, 2024
pulisher
Nov 11, 2024

Climb Bio Appoints Douglas E. Williams, Ph.D., as Chair of the Board - The Manila Times

Nov 11, 2024
pulisher
Nov 09, 2024

AC Immune SA Beat Analyst Profit Forecasts, And Analysts Have New Estimates - Yahoo Finance

Nov 09, 2024
pulisher
Nov 09, 2024

Leerink Partnrs Increases Earnings Estimates for AC Immune - Defense World

Nov 09, 2024
pulisher
Nov 08, 2024

FY2024 EPS Estimates for AC Immune Lifted by Leerink Partnrs - MarketBeat

Nov 08, 2024
pulisher
Nov 08, 2024

FY2024 EPS Estimates for AC Immune Boosted by HC Wainwright - MarketBeat

Nov 08, 2024
pulisher
Nov 08, 2024

HC Wainwright Reaffirms Buy Rating for AC Immune (NASDAQ:ACIU) - Defense World

Nov 08, 2024
pulisher
Nov 07, 2024

Brokers Set Expectations for AC Immune FY2027 Earnings - MarketBeat

Nov 07, 2024
pulisher
Nov 06, 2024

HC Wainwright Reiterates "Buy" Rating for AC Immune (NASDAQ:ACIU) - MarketBeat

Nov 06, 2024
pulisher
Nov 05, 2024

AC Immune: Q3 Earnings Snapshot - San Francisco Chronicle

Nov 05, 2024
pulisher
Nov 05, 2024

AC Immune reports Q3 EPS CHF 0.05 vs (CHF 0.18) last year - TipRanks

Nov 05, 2024
pulisher
Nov 05, 2024

AC Immune SA Reports Profitable Q3 2024 Results - TipRanks

Nov 05, 2024
pulisher
Nov 05, 2024

AC Immune Reports Third Quarter 2024 Financial Results and Provides a Corporate Update - The Manila Times

Nov 05, 2024
pulisher
Nov 05, 2024

AC Immune SA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 05, 2024
pulisher
Nov 03, 2024

Will ABATE Trial Data Lift AC Immune's Stock Price? - RTTNews

Nov 03, 2024
pulisher
Nov 03, 2024

Assenagon Asset Management S.A. Has $846,000 Stock Position in AC Immune SA (NASDAQ:ACIU) - MarketBeat

Nov 03, 2024
pulisher
Oct 30, 2024

Short Interest in AC Immune SA (NASDAQ:ACIU) Decreases By 7.4% - MarketBeat

Oct 30, 2024
pulisher
Oct 28, 2024

AC Immune SA (NASDAQ:ACIU) stock most popular amongst individual investors who own 32%, while private equity firms hold 29% - Yahoo Finance

Oct 28, 2024
pulisher
Oct 23, 2024

What To Expect From AC Immune SA (ACIU) Q3 2024 Earnings - Yahoo Finance

Oct 23, 2024
pulisher
Oct 23, 2024

Roche leaves Alzheimer partnership with UCB - European Biotechnology News

Oct 23, 2024
pulisher
Oct 22, 2024

UCB Assessing Bepranemab’s Future After Roche/Genentech Ends Partnership - Citeline

Oct 22, 2024
pulisher
Oct 18, 2024

Scrip Asks…What Does 2023 Hold For Biopharma? Part 5: Technological Advances - Citeline News & Insights

Oct 18, 2024
pulisher
Oct 15, 2024

AC Immune SA (NASDAQ:ACIU) Sees Significant Increase in Short Interest - MarketBeat

Oct 15, 2024
pulisher
Oct 15, 2024

AC Immune SA (NASDAQ:ACIU) Short Interest Up 12.9% in September - MarketBeat

Oct 15, 2024
pulisher
Oct 07, 2024

AC Immune (NASDAQ:ACIU investor three-year losses grow to 47% as the stock sheds US$40m this past week - Simply Wall St

Oct 07, 2024
pulisher
Oct 02, 2024

Renaissance Technologies LLC Has $2.60 Million Position in AC Immune SA (NASDAQ:ACIU) - MarketBeat

Oct 02, 2024
pulisher
Oct 01, 2024

AC Immune (NASDAQ:ACIU) Downgraded by StockNews.com - Defense World

Oct 01, 2024
pulisher
Oct 01, 2024

AC Immune (NASDAQ:ACIU) Downgraded by StockNews.com to Hold - MarketBeat

Oct 01, 2024
pulisher
Sep 24, 2024

Down Syndrome Market Forecasted to Surge in Coming Years, 2023-2032 Analysis by DelveInsight | AstraZeneca, Aelis Farma, AC Immune SA, Eisai Inc., Hoffmann-La Roche, Life Molecular Imaging SA - Barchart

Sep 24, 2024
pulisher
Sep 24, 2024

CompleCure, AGC Biologics Partner To Develop Advanced Anti-Cancer Therapy - Contract Pharma

Sep 24, 2024
pulisher
Sep 24, 2024

CompleCure Partners with AGC Biologics’ Chiba Site to Develop Advanced Anti-Cancer Therapeutic Using Pioneering AMDC Technology - AccessWire

Sep 24, 2024
pulisher
Sep 24, 2024

Why Industry Must Design Alzheimer's Trials To Include People With Down Syndrome - Clinical Leader

Sep 24, 2024

Ac Immune Sa Stock (ACIU) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$70.68
price down icon 0.42%
$18.62
price up icon 0.16%
$36.06
price down icon 1.68%
$364.60
price up icon 0.01%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Cap:     |  Volume (24h):